Case-control studies of patients with fractures have found that subjects with diabetes have at least a two fold higher risk than subjects without diabetes (1) , with increased risk of hip, humerus and foot fractures in elderly diabetic subjects (2) (3) (4) . Risk factors that contribute to increased fracture in diabetic subjects include number of falls (5; 6), insulin use (7; 8) , functional disability (9) (10) (11) , diabetes duration (7; 12) and poor vision (7) . Recent studies report that older women and African Americans have higher incidence of osteoporotic fractures (13) . In addition, lower bone strength (BMD) might be expected to increase risk for the development of osteoporosis and fracture.
Type 2 diabetes patients are widely prescribed drugs called thiazolidinediones which increases insulin sensitivity via activation of Peroxisome Proliferator-Activated Receptors (PPAR)-γ receptor. However, it is not known whether thiazolidinediones use has any effect on bone mass and thereby increases risk of fracture in type 2 diabetes patients. In animal studies, thiazolidinediones treatment was associated with bone loss in mouse model (14; 15) that was explained by possible imbalance in bone from increased apoptotic death of osteogenic cells and diminished bone formation (15) and in ovariectomized rats (16) . Other investigators did not find bone loss in troglitazone treated mice (17) . There is limited information on the effect of thiazolidinediones on BMD in humans. Recent study has suggested that thiazolidinedione use may cause bone loss in older women with type 2 diabetes (18) . The present study on 160 men with type 2 diabetes has examined BMD in patients on rosiglitazone treatment and compared with matched men with type 2 diabetes not on rosiglitazone treatment. This study shows that rosiglitazone treatment increases bone loss in men with type 2 diabetes.
Research Design and Methods:
After institutional review board approval, we retrieved the clinical data in the last four years of 354 subjects with diabetes and compared with the BMD data of age and BMI matched non-diabetic subjects. The clinical and BMD data between the two groups were compared. Among 354 subjects with diabetes, we had follow up BMD data for 32 men with type 2 diabetes receiving rosiglitazone and 128 men with type 2 diabetes not receiving any thiazolidinedione were considered as control group. The clinical data included are history of smoking, alcohol, hypertension, coronary artery disease, stroke, current medications, duration of diabetes; family history of diabetes and osteoporosis. Other details collected include height, weight, Body mass index (BMI), abdominal girth, hip/waist measurements and ratio and blood pressure. The dose of rosiglitazone was 4mg twice a day. We excluded the data of the subjects with chronic renal insufficiency, hyperparathyroidism, Cushing's syndrome and those who were on glucocorticoids and gonadotropin releasing hormone analogs.
BMD measurements were performed using dual energy x-ray absorptiometry ((Lunar Prodigy) at the lumbar spine -AP and lateral (L1-4) and the proximal femur (total hip, femoral neck, and trochanter) and 33% radius. The precision of DXA scans is 1-1.8%. Annualized absolute change in BMD was calculated as the difference between the results of the baseline and follow-up hip scans divided by the time between scans in years. Annualized percent change in BMD was calculated by dividing the annualized absolute change by the baseline BMD. We compared the BMD data of subjects with diabetes and on rosiglitazone compared to that of subjects with diabetes and not on rosiglitazone using unpaired t-test. A p value <0.05 on two-tailed testing was considered significant. Results and Discussion: The BMD data at both AP spine and hip in subjects with diabetes was similar to that of subjects with no diabetes, when matched for age and BMI (data not given here). Among men with type 2 diabetes, 160 subjects had a follow up DXA with a mean interval of 16 months that include 128 subjects with diabetes and not receiving rosiglitazone (control) as well as the 32 subjects with diabetes and receiving Rosiglitazone (study group). The BMD and clinical characteristics of subjects with type 2 diabetes are shown in Table 1 . There was no significant difference in the baseline BMD data at both Antero-Posterior (AP) spine and hip in subjects with type 2 diabetes with or without rosiglitazone. Since all the follow up DXA data was not collected at exact similar intervals, annualized percent changes were calculated. Annualized absolute percent changes in both groups were compared and the results are shown in Table 1. 3 BMD in subjects with type 2 diabetes was similar to non diabetic subjects. This finding is consistent with previous study (19) . Novel finding in our report is the adverse effect of rosiglitazone, a thiazolidinedione on skeletal health in humans. There was a significant difference in the BMD with loss of bone at both spine and hip in type 2 diabetes on rosiglitazone (Table 1 ). This study confirms the animal studies to show the possible adverse effect of rosiglitazone on skeletal health in men.
Osteoblasts and adipocytes are derived from a common multipotential mesenchymal stem cell (MSC) progenitor (18) (19) (20) .
PPAR-is essential for normal adipocyte differentiation and proliferation as well as fatty acid uptake and storage. Thiazolidinediones rosiglitazone and pioglitazone are commonly used to increase insulin sensitivity for the treatment of type 2 diabetes (21) . It has been shown that activation of PPAR 2 with rosiglitazone stimulates adipogenesis and inhibits osteoblastogenesis (22) . This may be a potential mechanism for loss of BMD in hips observed of rosiglitazone treated diabetic men.
This study is a retrospective study. The limitation of this study is that there were no bone turnover markers to compare; and the data groups are not large enough to perform regression analyses for the confounding factors such as age, duration of diabetes, use of insulin, association of hypertension and other factors such as smoking and alcoholism. Nevertheless, the study definitely shows a significant increase in bone loss both at total hip and femoral neck areas in type 2 diabetes on rosiglitazone treatment. This suggests that thiazolidinedione treatment is a risk factor and can contribute to excess incidence of fractures in diabetes. Acknowledgments: SY is supported by RGIA grant from Proctor and Gamble and Veterans Health Administration. SKJ is supported by NIDDK and Office of Dietary Supplements. 
